Angela Dispenzieri

98.6k total citations · 18 hit papers
976 papers, 47.8k citations indexed

About

Angela Dispenzieri is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Angela Dispenzieri has authored 976 papers receiving a total of 47.8k indexed citations (citations by other indexed papers that have themselves been cited), including 616 papers in Molecular Biology, 546 papers in Hematology and 291 papers in Oncology. Recurrent topics in Angela Dispenzieri's work include Multiple Myeloma Research and Treatments (486 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (427 papers) and Protein Degradation and Inhibitors (115 papers). Angela Dispenzieri is often cited by papers focused on Multiple Myeloma Research and Treatments (486 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (427 papers) and Protein Degradation and Inhibitors (115 papers). Angela Dispenzieri collaborates with scholars based in United States, Italy and United Kingdom. Angela Dispenzieri's co-authors include Morie A. Gertz, Robert A. Kyle, S. Vincent Rajkumar, Martha Q. Lacy, Shaji Kumar, John A. Lust, Philip R. Greipp, Suzanne R. Hayman, Rafaël Fonseca and Francis K. Buadi and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Angela Dispenzieri

931 papers receiving 46.8k citations

Hit Papers

Improved survival in mult... 2003 2026 2010 2018 2007 2003 2013 2006 2009 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Improved survival in multiple myeloma and the impact of novel therapies
    2007 1.7k citations Shaji Kumar, S. Vincent Rajkumar et al. Blood profile →
  2. Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
    2003 1.6k citations Robert A. Kyle, Morie A. Gertz et al. profile →
  3. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
    2013 957 citations Shaji Kumar, Angela Dispenzieri et al. profile →
  4. Prevalence of Monoclonal Gammopathy of Undetermined Significance
    2006 899 citations Robert A. Kyle, Terry M. Therneau et al. New England Journal of Medicine profile →
  5. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
    2009 743 citations Robert A. Kyle, Jerry A. Katzmann et al. Blood profile →
  6. Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
    2012 730 citations Shaji Kumar, Angela Dispenzieri et al. Journal of Clinical Oncology profile →
  7. Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis
    2004 639 citations Angela Dispenzieri, Morie A. Gertz et al. Journal of Clinical Oncology profile →
  8. New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
    2012 625 citations Giovanni Palladini, Angela Dispenzieri et al. Journal of Clinical Oncology profile →
  9. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
    2016 594 citations S. Vincent Rajkumar, Angela Dispenzieri et al. profile →
  10. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
    2007 580 citations Robert A. Kyle, Terry M. Therneau et al. New England Journal of Medicine profile →
  11. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System
    2016 475 citations Robert A. Kyle, Steven R. Zeldenrust et al. profile →
  12. Clonal competition with alternating dominance in multiple myeloma
    2012 456 citations Jonathan J. Keats, Marta Chesi et al. Blood profile →
  13. IMWG consensus on risk stratification in multiple myeloma
    2013 413 citations Wee Joo Chng, Angela Dispenzieri et al. profile →
  14. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
    2018 351 citations Robert A. Kyle, Dirk R. Larson et al. New England Journal of Medicine profile →
  15. Systemic immunoglobulin light chain amyloidosis
    2018 338 citations Giampaolo Merlini, Angela Dispenzieri et al. profile →
  16. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis
    2019 316 citations Giampaolo Merlini, Angela Dispenzieri et al. profile →
  17. Overview of Castleman disease
    2020 236 citations Angela Dispenzieri et al. Blood profile →
  18. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee
    2022 184 citations Angela Dispenzieri, Giampaolo Merlini et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Angela Dispenzieri United States 106 31.7k 25.5k 15.6k 9.3k 5.8k 976 47.8k
Morie A. Gertz United States 102 30.3k 1.0× 20.6k 0.8× 13.6k 0.9× 9.9k 1.1× 6.4k 1.1× 945 44.0k
Martha Q. Lacy United States 78 16.8k 0.5× 15.8k 0.6× 9.4k 0.6× 5.2k 0.6× 2.0k 0.3× 554 25.4k
Shaji Kumar United States 89 22.8k 0.7× 23.4k 0.9× 14.0k 0.9× 5.7k 0.6× 1.6k 0.3× 1.0k 35.0k
Philip R. Greipp United States 85 17.5k 0.6× 18.0k 0.7× 10.9k 0.7× 5.9k 0.6× 1.5k 0.3× 323 28.4k
Giampaolo Merlini Italy 87 22.6k 0.7× 4.6k 0.2× 5.8k 0.4× 6.3k 0.7× 5.5k 0.9× 569 27.9k
Thomas E. Witzig United States 101 11.2k 0.4× 9.6k 0.4× 13.5k 0.9× 8.6k 0.9× 762 0.1× 778 34.1k
Philippe Moreau France 89 17.9k 0.6× 19.7k 0.8× 14.4k 0.9× 4.4k 0.5× 659 0.1× 1.0k 32.4k
Rafaël Fonseca United States 84 16.2k 0.5× 17.5k 0.7× 9.9k 0.6× 5.8k 0.6× 708 0.1× 441 25.8k
Philip N. Hawkins United Kingdom 95 25.9k 0.8× 3.0k 0.1× 4.9k 0.3× 3.0k 0.3× 7.5k 1.3× 556 33.6k
Bart Barlogie United States 109 24.5k 0.8× 30.7k 1.2× 18.3k 1.2× 5.7k 0.6× 316 0.1× 704 42.4k

Countries citing papers authored by Angela Dispenzieri

Since Specialization
Citations

This map shows the geographic impact of Angela Dispenzieri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angela Dispenzieri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angela Dispenzieri more than expected).

Fields of papers citing papers by Angela Dispenzieri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angela Dispenzieri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angela Dispenzieri. The network helps show where Angela Dispenzieri may publish in the future.

Co-authorship network of co-authors of Angela Dispenzieri

This figure shows the co-authorship network connecting the top 25 collaborators of Angela Dispenzieri. A scholar is included among the top collaborators of Angela Dispenzieri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angela Dispenzieri. Angela Dispenzieri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chiu, April, Surendra Dasari, Samih H. Nasr, et al.. (2024). Salivary gland amyloidosis: Proteomic identification and clinicopathologic characterization of 57 cases. Human Pathology. 151. 105628–105628. 1 indexed citations
2.
Abbasi, Muhannad, et al.. (2024). Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis. JACC CardioOncology. 6(2). 313–314.
3.
Abdallah, Nadine, Amanika Kumar, Betsy LaPlant, et al.. (2024). Cumulative deficits frailty index and relationship status predict survival in multiple myeloma. Blood Advances. 9(5). 1137–1146. 1 indexed citations
4.
Hagen, Catherine E., Surendra Dasari, Jason D. Theis, et al.. (2023). Gastrointestinal amyloidosis: an often unexpected finding with systemic implications. Human Pathology. 139. 27–36. 6 indexed citations
5.
Hwa, Yi L., Martha Q. Lacy, Morie A. Gertz, et al.. (2020). Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. European Journal Of Haematology. 106(3). 433–436. 2 indexed citations
6.
Saleh, Abdullah S. Al, M Hasib Sidiqi, Eli Muchtar, et al.. (2019). Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. Biology of Blood and Marrow Transplantation. 25(8). 1520–1525. 7 indexed citations
7.
Venkatesh, Sudhakar K., Sudhakar K. Venkatesh, Angela Dispenzieri, et al.. (2019). Magnetic Resonance Elastography of Liver in Light Chain Amyloidosis. Journal of Clinical Medicine. 8(5). 739–739. 16 indexed citations
8.
Saleh, Abdullah S. Al, M Hasib Sidiqi, Surbhi Sidana, et al.. (2019). Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. American Journal of Hematology. 94(10). 1066–1071. 13 indexed citations
9.
Dasari, Surendra, Mariam P. Alexander, Julie A. Vrana, et al.. (2017). DnaJ Heat Shock Protein Family B Member 9 Is a Novel Biomarker for Fibrillary GN. Journal of the American Society of Nephrology. 29(1). 51–56. 71 indexed citations
10.
Sanchorawala, Vaishali, Giovanni Palladini, Vishal Kukreti, et al.. (2017). A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 130(5). 597–605. 101 indexed citations
11.
Kourelis, Taxiarchis, Surendra Dasari, Jason D. Theis, et al.. (2016). Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. Blood. 129(3). 299–306. 106 indexed citations
12.
Kapoor, Prashant, Shaji Kumar, Angela Dispenzieri, et al.. (2013). Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology. 31(36). 4529–4535. 120 indexed citations
13.
Keats, Jonathan J., Marta Chesi, Jan B. Egan, et al.. (2012). Clonal competition with alternating dominance in multiple myeloma. Blood. 120(5). 1067–1076. 456 indexed citations breakdown →
14.
Wadhera, Rishi K., Robert A. Kyle, Dirk R. Larson, et al.. (2011). Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood. 118(11). 2985–2987. 29 indexed citations
15.
Ghobrial, Irene M., Morie A. Gertz, Betsy LaPlant, et al.. (2010). Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia. Journal of Clinical Oncology. 28(8). 1408–1414. 102 indexed citations
16.
Kumar, Shaji, Angela Dispenzieri, Jerry A. Katzmann, et al.. (2010). Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 116(24). 5126–5129. 121 indexed citations
17.
Lacy, Martha Q., Suzanne R. Hayman, Morie A. Gertz, et al.. (2009). Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology. 27(30). 5008–5014. 226 indexed citations
18.
Vachon, Celine M., Robert A. Kyle, Terry M. Therneau, et al.. (2009). Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 114(4). 785–790. 87 indexed citations
19.
Chng, Wee Joo, Shaji Kumar, Scott VanWier, et al.. (2007). Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling. Cancer Research. 67(7). 2982–2989. 195 indexed citations
20.
Kyle, Robert A., Terry M. Therneau, S. Vincent Rajkumar, et al.. (2006). Prevalence of Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine. 354(13). 1362–1369. 899 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Morie A. Gertz Breakdown of academic impact, for papers by Martha Q. Lacy Breakdown of academic impact, for papers by Shaji Kumar Breakdown of academic impact, for papers by Philip R. Greipp Breakdown of academic impact, for papers by Giampaolo Merlini Breakdown of academic impact, for papers by Thomas E. Witzig Breakdown of academic impact, for papers by Philippe Moreau Breakdown of academic impact, for papers by Rafaël Fonseca Breakdown of academic impact, for papers by Philip N. Hawkins Breakdown of academic impact, for papers by Bart Barlogie
Rankless by CCL
2026